- Home
- AZZ vs ARQT Comparison
AZZ vs ARQT Comparison
Compare AZZ & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZZ | ARQT |
|---|---|---|
| Founded | 1956 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.3B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AZZ | ARQT |
|---|---|---|
| Price | $133.55 | $24.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $126.00 | $34.00 |
| AVG Volume (30 Days) | 131.5K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 9.97 | N/A |
| Revenue | ★ $1,061,817,000.00 | $376,072,000.00 |
| Revenue This Year | $5.47 | $34.85 |
| Revenue Next Year | $6.13 | $29.39 |
| P/E Ratio | $13.44 | ★ N/A |
| Revenue Growth | 14.53 | ★ 91.34 |
| 52 Week Low | $74.00 | $12.42 |
| 52 Week High | $141.18 | $31.77 |
Technical Indicators
Market Signals| Indicator | AZZ | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 50.61 |
| Support Level | $130.88 | $22.56 |
| Resistance Level | $141.18 | $25.03 |
| Average True Range (ATR) | 3.62 | 0.99 |
| MACD | 1.01 | 0.25 |
| Stochastic Oscillator | 65.84 | 66.44 |
Price Performance
Historical ComparisonAbout AZZ AZZ Inc.
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.